drugset / Trial / NCT06271265

Study to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Undergoing Cardiac Surgery

NCT06271265

Phase 1 Recruiting 48 enrolled Pacira Pharmaceuticals, Inc
RandomizedSingle-groupOpen-labelTreatment

Summary

This Phase 1, multicenter, open-label, randomized, bupivacaine-controlled study is designed to evaluate the pharmacokinetics (PK) and safety of EXPAREL vs. bupivacaine HCl for postsurgical analgesia in pediatric subjects aged 0 to less than 6 years of age undergoing cardiac surgery, utilizing local infiltration analgesia (LIA).

Timeline

Start
2024-03-29
Primary completion
2027-01
Completion
2027-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bupivacaine Other / unclassified 2 mg/kg Other
Comparator Bupivacaine Other / unclassified 4 mg/kg Other

Indications

No indication recorded.